Time course of endogenous nitric oxide inhibitors in severe sepsis in humans

Minerva Anestesiologica

Volumn 76, Issue 5, 2010, Pages 325-333

  Iapichino, G ^a   Umbrello, M ^a   Albicini, M ^a   Spanu, P ^a   Bellani, G ^b   Polli, F ^a   Pavlovic, R ^a   Cugno, M ^a   Fermo, I ^c   Paroni, R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Critical illness; Nitric oxide; Sepsis

Indexed keywords

6 N,N' DIMETHYLARGININE; ARGININE; C REACTIVE PROTEIN; INTERLEUKIN 6; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; DIMETHYLARGININE; DRUG DERIVATIVE;

ADULT; ARTICLE; CATABOLISM; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; SEPSIS; SEQUENTIAL ORGAN FAILURE ASSESSMENT; SIMPLIFIED ACUTE PHYSIOLOGIC SCORE; SURVIVAL RATE; UREA BLOOD LEVEL; AGED; BLOOD; BLOOD ANALYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; KINETICS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

AGED; ARGININE; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; FEMALE; HUMANS; INTENSIVE CARE; KINETICS; MALE; MIDDLE AGED; NITRIC OXIDE; SEPSIS; SURVIVAL;

EID: 77954676829     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. McBride AE, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell 2001; 106:5-8.
2. Biolo G, De Cicco M, Lorenzon S, Dal Mas V, Fantin D, Paroni R et al. Treating hyperglycemia improves skeletal muscle protein metabolism in cancer patients after major surgery. Crit Care Med 2008;36:1768-1775.
3. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E et al. Marked increase of symmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 2002;13:170-176.
4. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20 Suppl 12:S60-S62.
5. Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006;17:1128-1134.
6. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997;1:65-73.
7. Richir MC, Bouwman RH, Teerlink T, Siroen MP, de Vries TP, van Leeuwen PA. The prominent role of the liver in the elimination of asymmetric dimethylarginine (ADMA) and the consequences of impaired hepatic function. JPEN J Parenter Enteral Nutr 2008;32:613-621.
8. Nijveldt RJ, Teerlink T, van Der Hoven B, Siroen MP, Kuik DJ, Rauwerda JA et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin Nutr 2003;22:23-30.
9. Siroen MP, van Leeuwen PA, Nijveldt RJ, Teerlink T, Wouters PJ, Van den Berghe G. Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? Crit Care Med 2005;33:504-510.
10. O'Dwyer MJ, Dempsey F, Crowley V, Kelleher DP, McManus R, Ryan T. Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit Care 2006; 10: R139.
11. Maas R, Dentz L, Schwedhelm E, Thoms W, Kuss O, Hiltmeyer N et al. Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery. Crit Care Med 2007;35:1876-1881.
12. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-2117.
13. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001;358:2127-2128.
14. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003;24:1912-1919.
15. Kielstein JT, Bode-Boger SM, Hesse G, Martens-Lobenhoffer J, Takacs A, Fliser D et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005;25:1414-1418.
16. Lopez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 2004; 32:21-30.
17. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-3095.
18. Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 2006;26:203-228.
19. Zoccali C, Maas R, Cutrupi S, Pizzini P, Finocchiaro P, Cambareri F et al. Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. Nephrol Dial Transplant 2007;22:801-6.
20. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethyla minohydrolase. Circ Res 2003;92:226-233.
21. Savioli M, Cugno M, Polli F, Taccone P, Bellani G, Spanu P et al.Tight glycemic control may favor fibrinolysis in patients with sepsis. Crit Care Med 2009;37:424-431.
22. Polli F, Savioli M, Cugno M, Taccone P, Bellani G, Spanu P et al. Effects of recombinant human activated protein C on the fibrinolytic system of patients undergoing conventional or tight glycemic control. Minerva Anestesiol 2009;75:417-426.
23. Iapichino G, Albicini M, Umbrello M, Sacconi F, Fermo I, Pavlovich R et al.Tight glycemic control does not affect asymmetric- dimethylarginine in septic patients. Intensive Care Med 2008;34:1843-1850.
24. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.
25. Umbrello M, Albicini M, Spanu P, Curti M, Zona V, Polli F et al. Tight glycemic control (TGC) and dimethylarginines in septic patients. Clin Nutr 2008;3 Suppl 1:5-6.
26. Le Gall JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. JAMA 1993;270:2957-63.
27. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996;22:707-10.
28. Paroni R, Fermo I, Fiorina P, Cighetti G. Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids 2005;28:389-394.
29. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992;215:356-62.
30. Boger RH. L-Arginine therapy in cardiovascular pathologies: beneficial or dangerous? Curr Opin Clin Nutr Metab Care 2008;11:55-61.